Hasil Pencarian  ::  Simpan CSV :: Kembali

"Latar belakang: Diabetes mellitus tipe 2 (DMT2) dan gagal jantung memiliki keterkaitan yang kuat dan luaran klinis yang satu mempengaruhi lainnya. Studi terakhir berhasil membuktikan manfaat empagliflozin, obat lini kedua pada DMT2, terhadap kardiovaskular. Mekanisme seluler yang diketahui berperan pada hewan adalah efek antifibrosis miokard, namunbelum ada studi pada manusia.Tujuan: Mengetahui efek pemberian empagliflozin terhadap fibrosis miokard pada pasien DMT2 dengan gagal jantung. Metode: Uji klinis acak tidak tersamar yang dilakukan di RS Jantung dan Pembuluh Darah Harapan Kita dari Februari 2019 sampai Mei 2019. Pasien DMT2 dan gagal jantung diberikan empagliflozin 10 mg selama tiga bulan. Perbedaan kadar suppression of tumorigenicity-2 (ST2) serum pada kelompok kontrol dan intervensi di awal dan akhir penelitian akan dianalisis. Hasil: Terdapat 58 pasien yang menjadi subjek penelitian dan 40 (69%) pasien menyelesaikan penelitian. Terdapat perbedaan kadar ST2 yang bermakna setelah pemberian empagliflozin selama tiga bulan (median ST2 kelompok empagliflozin sebelum dan sesudah empagliflozin masing-masing 23,5(12,5 - 130,7)ng/mL dan 18,9(12,5 - 29,4) ng/mL, p=0,02). Penurunan ST2 dan persentase penurunan ST2 kelompok empagliflozin kedua kelompok tidak berbeda secara statistik (masing-masing p=0,16 dan p=0,21). Kesimpulan: Pemberian empagliflozin selama tiga bulan dapat menurunkan fibrosis miokard yang tidak terlihat pada kelompok kontrol. Tidak terdapat perbedaan besaran penurunan fibrosis pada pemberian empagliflozin dibandingkan terapi standar.

---

Background: Type 2 diabetes mellitus (T2DM) and heart failure have a strong relationship; one affects each other. Recent studies have proven some cardiovascular benefits of empagliflozin. Myocardial antifibrosis is proposed to be the mechanism in many animal studies, but in humans the data is lack. Objectives: To investigate the effect of empagliflozin on myocardial fibrosis in T2DM patients and heart failure. Methods: This was an open-labeled clinical trial in National Cardiovascular Center Harapan Kita, from February 2019 to May 2019. Patients with T2DM and heart failure received empagliflozin 10 mg for three months. Differences of serum suppression of tumorigenicity-2 (ST2) levels in both control and intervention groups at the beginning and end of the study were analyzed. Results: There were 58 patients enrolled in the study and total of 40 (69%) patients completed it. There were significant differences in ST2 levels after administration of empagliflozin (median for ST2 empagliflozin group before and after empagliflozin was 23.5 (12.5 - 130.7) ng / mL and 18.9 (12, 5 - 29.4) ng / mL respectively, p = 0.02). The ST2 value difference and percent different were not different (p=0,16 and p=0,21, respectively). Conclusion: Three months Empagliflozin might reduce myocard fibrosis which was not seen in control group. The total fibrosis reduction was not significantly different compared to standard therapy"

"Latar belakang: Gagal jantung merupakan beban baik dalam hal prognostik maupun sosial ekonomi. Gagal jantung dan diabetes melitus tipe 2 (DMT2) saling mempengaruhi luaran klinis pasien. Empagliflozin, suatu penghambat SGLT2, merupakan agen antihiperglikemia baru yang terbukti dapat menurunkan mortalitas dan hospitalisasi akibat gagal jantung. Beberapa mekanisme efek proteksi empagliflozin terhadap kardiovaskular telah dibuktikan melalui studi pada hewan. Empagliflozin memiliki efek meningkatkan fungsi sistolik ventrikel kiri pada hewan coba. Namun efek Empagliflozin terhadap fungsi sistolik intrinsik ventrikel kiri pada pasien DMT2 dengan gagal jantung belum diketahui.Tujuan: Mengetahui pengaruh pemberian Empagliflozin terhadap fungsi sistolik intrinsik ventrikel kiri pada pasien DMT2 dengan gagal jantungMetode: Penelitian ini merupakan uji klinis acak tidak tersamar yang dilakukan di poliklinik Rumah Sakit Jantung dan Pembuluh Darah Harapan Kita (RSJPDHK) pada pasien DMT2 dengan gagal jantung. Kelompok yang mendapat Empagliflozin 10 mg selama 3 bulan dibandingkan terhadap kelompok kontrol dengan terapi standar. Dilakukan pemeriksaaan global longitudinal strain (GLS) dengan speckle tracking echocardiography (STE) sebelum dan setelah terapi diberikan.Hasil: Total terdapat 41 pasien menyelesaikan penelitian (21 kelompok empagliflozin, 20 kelompok kontrol). Setelah 3 bulan follow up, nilai GLS kelompok empagliflozin cenderung tetap (rerata perubahan GLS 0,06%), sedangkan pada kelompok kontrol terdapat perburukan nilai GLS dengan rerata 1,5%, perbedaan kedua kelompok bermakna secara statistik (p 0,04). Kesimpulan: Terdapat perbedaan perubahan fungsi sistolik intrinsik ventrikel kiri setelah pemberian empagliflozin pada pasien diabetes melitus tipe 2 dengan gagal jantung dibandingkan terapi standar.

---

Background: Heart failure is a burden both in terms of prognostic and socio-economic. Heart failure and type 2 diabetes mellitus (T2DM) have a strong relationship in influencing patient s clinical outcome. Empagliflozin, an SGLT2 inhibitor, is a new antihyperlglycemic agent that has been shown to reduce mortality and hospitalization due to heart failure. Several mechanisms of cardioprotective effect of empagliflozin have been demonstrated in animal studies. Empagliflozin has proven to increase left ventricular systolic function in animal study. However, its effect on left ventricular intrinsic systolic function in T2DM patients with heart failure is unknown.

Objectives: Knowing the effect of empagliflozin on left ventricular intrinsic systolic function in T2DM patients with heart failure.

Methods: This is a randomized, open label, clinical trial, which was conducted at National Cardiovascular Center Harapan Kita (NCCHK) hospital outpatient clinic. The group who received 10 mg empagliflozin for 3 months was compared with control group. Global longitudinal strain (GLS) by speckle tracking echocardiography was examined before and after therapy was given.

Results: A total of 41 patients completed the study (21 in empagliflozin group, and 20 in control group). After 3 months of follow-up, the GLS in empagliflozin group remained constant (mean changes in GLS was 0.06%), whereas in the control group there was a deterioration in GLS with an average of 1.5%, the difference between the two groups was statistically significant (p 0.04).

Conclusion: There is a difference in left ventricular intrinsic systolic function after administration of empagliflozin in T2DM patients with heart failure compared to standard therapy."

"Latar belakang: Gagal jantung kongestif atau congestive heart failure CHF dan diabetes melitus DM tipe 2 merupakan dua kondisi yang saling memberatkan, yaitu terjadi gangguan metabolisme yang lebih berat akibat perubahan neurohormonal, dan struktur jantung yang berpotensi memperburuk prognosis. Tatalaksana nutrisi sejak awal diagnosis sangat penting dalam mendukung proses penyembuhan pasien dan mencegah komplikasi lebih lanjut. Kasus: Dalam serial kasus ini terdapat empat pasien CHF dan DM tipe 2 dengan penyulit. Keempat pasien dengan hipertensi dan hiperurisemia, tiga pasien dengan status gizi obes, tiga pasien dengan infark miokard, satu pasien dengan unstable angina pectoris, dua pasien dengan acute kidney injury, dan satu pasien dengan chronic kidney disease. Pada awal pemeriksaan didapatkan defisiensi asupan makro- dan mikronutrien, kontrol tekanan darah dan glukosa darah yang kurang baik, retensi cairan, dan penurunan kapasitas fungsional. Tatalaksana nutrisi disesuaikan secara individual, berdasarkan kondisi klinis, hasil laboratorium dan pemeriksaan penunjang lainnya serta riwayat asupan makanan. Hasil: Seluruh pasien mengalami peningkatan toleransi asupan, perbaikan kondisi klinis, dan kapasitas fungsional. Kesimpulan: Tatalaksana nutrisi yang adekuat pada pasien CHF dan DM tipe 2 dengan penyulit dapat mendukung perbaikan kondisi klinis dan kapasitas fungsional, sehingga dapat menurunkan morbiditas dan mortalitas.

---

Background: Congestive heart failure CHF and type 2 diabetes mellitus DM are two mutually aggravating conditions, with more severe metabolic abnormalities due to changes in neurohormonal and cardiac structure which potentially worsen the prognosis. Nutritional management since early diagnosis is very important in supporting the healing process of patients and prevent further complications.

Cases: Four patients were diagnosed with CHF and type 2 DM with complicating conditions. Four patients with hypertension and hyperuricemia, three patients were obese, three patients experienced myocard infarct one patient had unstable angina pectoris, two patients had acute kidney injury, and one patient had chronic kidney disease. Nutritional problems in four patients at assessment were macro and micronutrient deficiencies, uncontrolled blood pressure and blood glucose, fluid retention and declined functional capacity. Nutrition therapy were planned individually including macronutrients, micronutrients and fluid intakes, based on clinical conditions, laboratory findings, other examinations, and previous food intakes.

Result: There were improvements of clinical conditions, intake tolerance, and functional capacity.

Conclusion: Adequate nutrition therapy for CHF and type 2 DM patients with complicating conditions supports the improvements of clinical condition and functional capacity, decreasing morbidity and mortality rates. "

"Latar belakang: Pasien gagal jantung sering mengalami readmisi dengan tingkat mortalitas yang tinggi sehingga diperlukan deteksi dini dan tatalaksana yang tepat untuk memperbaiki prognosis. Resiko rawat inap akibat gagal jantung bahkan lebih meningkat pada pasien diabetes mellitus (DM) tipe 2, yaitu 1.5x lebih tinggi. Menggunakan kecerdasan buatan, dapat dilakukan integrasi antara data klinis dengan pemeriksaan penunjang seperti EKG dan rontgen thorax. Selain itu, kecerdasan buatan juga dapat membantu diagnosis di bidang kardiovaskular tanpa adanya variabilitas antar pengamat, serta meningkatkan efisiensi waktu dan biaya.Tujuan: Penelitian ini bertujuan untuk membandingkan kemampuan kecerdasan buatan dengan statistik konvensional dalam memprediksi luaran klinis lama rawat, readmisi 30 hari, mortalitas 180 hari, dan luaran gabungan pada pasien gagal jantung dekompensasi akut (GJDA) dengan penurunan fraksi ejeksi dan DM tipe 2.Metode: Dilakukan studi kohort retrospektif terhadap pasien GJDA dengan penurunan fraksi ejeksi dan DM tipe 2 pada periode Januari 2018 – Maret 2023. Dilakukan analisis data menggunakan statistik konvensional dengan analisis bivariat dan multivariat, dimana hasilnya kemudian dibandingkan dengan analisis menggunakan algoritme kecerdasan buatan, yaitu Balanced Random Forest.Hasil: Melalui rekam medis, didapatkan 292 subjek penelitian dengan persentase lama rawat >5 hari, readmisi 30 hari, mortalitas 180 hari, dan luaran gabungan yang diobservasi adalah 39.7%, 14.0%, 10.6%, dan 21.2% berturut-turut. Kemampuan diskriminasi kecerdasan buatan lebih baik dibandingkan statistik konvensional untuk keempat luaran, dengan AUC lama rawat >5 hari adalah 0.800 vs 0.775, readmisi 0.790 vs 0.732, mortalitas 0.794 vs 0.785, dan luaran gabungan 0.628 vs 0.596.Kesimpulan: Kecerdasan buatan lebih baik dibandingkan statistik konvensional untuk memprediksi luaran klinis berupa lama rawat, readmisi 30 hari, mortalitas 180 hari, dan luaran gabungan pada pasien GJDA dengan penurunan fraksi ejeksi dan DM tipe 2.

---

Background: Heart failure patients often experience readmissions with a high mortality rate, therefore early detection and appropriate management are required to improve the prognosis. The risk of hospitalization due to heart failure is increased 1.5x in type 2 diabetes mellitus (DM) patients. Using artificial intelligence, clinical data can be integrated with supporting examinations such as ECG and chest X-ray. Artificial intelligence can also help diagnoses in the cardiovascular field without inter-observer variability, as well as increasing time and cost efficiency.

Objective: This study aims to compare the ability of conventional statistics with artificial intelligence in predicting clinical outcomes, namely length of stay, 30-day readmission, 180- day mortality, and composite outcome in acute decompensated heart failure (ADHF) patients with reduced ejection fraction and type 2 DM.

Methods: A retrospective cohort study was conducted on 292 ADHF patients with reduced ejection fraction and type 2 DM in the period January 2018 – March 2023. Data analysis was carried out using conventional statistics with bivariate and multivariate analysis, where the results were then compared with analysis using artificial intelligence algorithm, namely Balanced Random Forest.

Results: The percentages of outcomes observed for length of stay >5 days, 30 day readmission, 180 day mortality, and composite outcome were 39.7%, 14.0%, 10.6%, and 21.2% respectively. The discrimination ability of artificial intelligence was better than conventional statistics for all four outcomes, with the AUC of length of stay >5 days were 0.800 vs 0.775, readmission 0.790 vs 0.732, mortality 0.794 vs 0.785, and combined outcome 0.628 vs 0.596.

Conclusion: Artificial intelligence is better than conventional statistics in predicting clinical outcomes in the form of length of stay, 30-day readmission, 180-day mortality, and composite outcome in ADHF patients with reduced ejection fraction and type 2 DM."

"Pemantauan terapi obat adalah kegiatan untuk memastikan terapi obat yang aman, efektif, dan rasional bagi pasien dengan mengkaji pemilihan obat, dosis, cara pemberian obat, respons terapi, reaksi obat yang tidak dikehendaki, dan rekomendasi perubahan atau alternatif terapi. Kondisi pasien yang perlu dilakukan pemantauan terapi obat antara lain pasien hamil dan menyusui, pasien yang menerima regimen yang kompleks (polifarmasi) serta pasien geriatri dan pediatri. Tujuan laporan PKPA ini adalah untuk menganalisa dan mengevaluasi drug related problem (DRP) pada pasien dan diklasifikasikan sesuai kategori Hepler dan Strand. Kegiatan dilakukan melalui pengambilan data pasien dengan diagnosis syok kardiogenik dengan gagal jantung, gangguan ginjal akut, DM tipe 2, dan hipokalemia. Data yang diambil merupakan kombinasi data primer dan sekunder. Berdasarkan hasil analisis, diketahui bahwa pengobatan yang diterima oleh pasien hampir seluruhnya tepat indikasi dan dosis kecuali dosis pada sukralfat dan allopurinol yang melebihi rentang dosis seharusnya. Selain itu, ditemukan DRP berupa interaksi obat yang bersifat potensial, pemilihan obat tidak tepat, serta indikasi tanpa obat. DRP tersebut telah diatasi dengan pemberian terapi yang sesuai.

---

Drug therapy monitoring is an activity to ensure safe, effective, and rational drug therapy for patients by reviewing the selection of drugs, dosages, methods of drug administration, therapeutic response, unwanted drug reactions, and recommendations for changes or alternative therapies. Patients who need to be monitored for drug therapy include pregnant and lactating patients, patients receiving complex regimens (polypharmacy), as well as geriatric and pediatric patients. The purpose of this PKPA report is to analyze and evaluate drug-related problems (DRP) in patients and classify them according to the Hepler and Strand categories. Activities are carried out through the data collection of patients with a diagnosis of cardiogenic shock with heart failure, acute kidney disorder, type 2 DM, and hypokalemia. The data was took is a combination of primary and secondary data. Based on the results of the analysis, it was known that the treatment received by the patients was almost entirely in accordance with the right indication and dosage, except for the doses of sucralfate and allopurinol, which exceeded the proper dosage range. In addition, DRP was found in the form of potential drug interactions, inappropriate drug selection, and indications without drugs. The DRP has been overcome by administering appropriate therapy."

"ABSTRAKKontrol glukosa darah dapat dipertahankan melalui perawatan mandiri. Motivasi melakukan self monitoring blood glucose (SMBG) yang baik dapat meningkatkan diabetes self management pada pasien diabetes melitus tipe 2.Tujuan penelitian ini adalah untuk mengetahui hubungan motivasi melakukan SMBG dengan diabetes self management pada pasien diabetes melitus tipe 2.Penelitian ini menggunakan metode kuantitatif observasional analitik dengan pendekatan crossectional, melibatkan 96 pasien. Alat ukur yang digunakan berupa kuesioner karakteristik responden, Treatment Self Regulation Questionare, Diabetes Self Management Questionare, Diabetes Knowledge Scale.Hasil penelitian menunjukkan terdapat hubungan yang bermakna antara motivasi melakukan SMBG dengan diabetes self management (p = 0,001). Hasil analisis regresi logistik menunjukkan motivasi melakukan SMBG berhubungan dengan didabetes self management setelah dikontrol variabel pengetahuan.Kesimpulan diperlukan perhatian khusus dari perawat untuk meningkatkan motivasi melakukan SMBG pada pasien diabetes melitus tipe 2 dalam self care management.

---

ABSTRACT

Glycemic control could be maintained through diabetes self-management. Motivation to perform self-monitoring blood glucose (SMBG) could improve diabetes self-management in type 2 diabetes mellitus patients.

The purpose of this study was to explore the relationship between motivation to perform SMBG and diabetes self-management in patients with type 2 diabetes mellitus.

This study applied quantitative method with a cross sectional approach, involving 96 patients. The Instruments used were questionnaires for respondent characteristics, Treatment Self-Regulation Questionnaires, Diabetes Self Management Questionnaire and Diabetes Knowledge Scale.

The results show that there was a significant relationship between motivation to perform SMBG and diabetes selfmanagement (p = 0,001). Results of logistic regression analysis showes that motivation to perform SMBG is associated with diabetes self-management after controlled by knowledge variable.

In conclusion it is a necessarily for nurses to provide attention to increase motivation to perform SMBG in patients with type 2 diabetes mellitus as part of self care management."

"ABSTRAKDiabetes Melitus Tipe 2 (DMT2) adalah masalah global yang sangat serius. Penyakit ini menyerang pada usia yang paling produktif sehingga dapat menurunkan derajat ekonomi dan mengurangi usia harapan hidup. Patogenesis DM sangat erat kaitannya dengan inflamasi, ditandai dengan peningkatan kadar sitokin proinflamasi seperti IL-6, IL-8 dan TNF. Namun, belum ada agen antiinflamasi yang terbukti berperan dalam tatalaksana DMT2. Butirat merupakan asam lemak rantai pendek yang diproduksi dari fermentasi pati resisten di lumen usus. Dalam kondisi normal butirat diserap dan digunakan sebagai sumber energi bagi sel kolonosit, hati dan otot. Butirat mampu berikatan dengan reseptor GPR41 dan GPR43 pada monosit sehingga mampu mengubah pola ekspresi sitokin, aktivasi, migrasi dan diferensiasi sel. Sehingga menarik untuk meneliti pengaruh butirat terhadap migrasi dan sitokin yang diekspresikan oleh monosit pada pasien DMT2. Kadar sitokin dihitung dari supernatan yang diambil dari kultur monosit . Sebanyak 37 subJek dibagi menjadi dua perlakuan yaitu kontrol dan dengan penambahan butirat. Monosit hari pertama diisolasi dalam gel kolagen tipe 1 untuk dilakukan uji migrasi menggunakan μ-slide chemotaxis IBIDI. Analisis gambar menggunakan software ImageJ dan Chemotaxis tool. Terdapat adanya perbedaan yang bermakna pada rasio TNF/IL 10 antara kelompok sehat dan DMT2. Butirat juga terlihat menekan produksi sitokin TNF dan meningkatkan produksi IL10. Indikator migrasi monosit seperti jarak akumulasi dan kecepatan migrasi memiliki perbedaan bermakna antara kelompok sehat dan DMT2. Butirat dapat menekan laju migrasi monosit diikuti dengan penurunan jarak dan kecepatan migrasi monosit

---

ABSTRACTType 2 Diabetes Mellitus (DMT2) is a very serious global problem. This disease attacks at the most productive age so that it can reduce economic status and reduce life expectancy. The pathogenesis of DM is very closely related to inflammation. characterized by increased levels of proinflammatory cytokines such as IL-6, IL-8 and TNF. However, no anti-inflammatory agent has been proven to play a role in the management of T2DM. Butyrate is a short chain fatty acid produced from resistant starch fermentation in the intestinal lumen. In normal conditions the butyrate is absorbed and used as an energy source for colonocytes, liver and muscle cells. Butirate is able to bind to GPR41 and GPR43 receptors on monocytes so that it can change the pattern of cytokine expression, activation, migration and cell differentiation. So it is interesting to examine the effect of butyrate on migration and cytokines expressed by monocytes in T2DM patients. Cytokine levels were calculated from supernatants taken from monocyte cultures. A total of 37 subjects were divided into two treatments, namely control and with addition of butyrate. The first day monocytes were isolated in type 1 collagen gel for migration testing using the slide chemotaxis IBIDI. Image analysis using ImageJ and Chemotaxis tool software. There was a significant difference in the TNFα / IL 10 ratio between healthy groups and T2DM. Butyrate also appears to suppress TNF cytokine production and increase IL10 production. Monocyte migration indicators such as accumulation distance and migration speed have significant differences between healthy groups and T2DM. Butirat can reduce inflammation responds and the distance and speed of monocyte migration"

"Latar Belakang: Kongesti merupakan penyebab utama pada kondisi perburukan dari gagal jantung kronis yang disebut juga sebagai gagal jantung dekompensasi akut (GJDA). Pemeriksaan status kongesti intravaskular pada pasien GJDA dengan fraksi ejeksi rendah dan diabetes mellitus (DM) sangat penting dilakukan karena mempengaruhi prognosis dan memiliki angka kematian dan readmisi yang lebih tinggi. Pemeriksaan status volume intravaskular pada populasi ini dinilai sulit karena terjadi peningkatan permeabilitas dinding vaskular, sehingga lebih banyak terjadi kongesti interstitial. Beberapa penelitian menggunakan perhitungan estimasi volume plasma (eVP) dengan membandingkan kadar hemoglobin dan hematokrit sebagai indikator adanya kongesti intravaskular yang berperan sebagai modalitas prognostik pada pasien GJDA dan DM tipe 2.Tujuan: Untuk mengetahui hubungan antara estimasi volume plasma (eVP) terhadap luaran lama rawat, readmisi 30 hari dan mortalitas 180 hari pada pasien GJDA dengan fraksi ejeksi rendah dan DM tipe-2.Metode: Penelitian kohort retrospektif dengan populasi penelitian pasien dengan GJDA dan DM tipe 2 selama periode Januari 2016 sampai dengan Januari 2021 di Rumah Sakit Jantung dan Pembuluh Darah Harapan Kita.Hasil: Sebanyak 373 pasien yang memenuhi kriteria inklusi, Nilai eVP awal > 5,04 ml/g berhubungan secara bermakna terhadap mortalitas 180 hari dengan sensitifitas 61% dan spesifisitas 59% (HR 2,12; IK95 1,13-3,98; p = 0,019). Nilai eVP akhir berhubungan secara bermakna terhadap readmisi 30 hari (OR 1,23; IK95 1,05 – 1,46; p = 0,025). Nilai eVP akhir secara bermakna berkorelasi positif dengan lama rawat inap (koefisien B 0,412, p = 0,02).Kesimpulan: Nilai estimasi volume plasma yang tinggi berhubungan dengan lama rawat, readmisi 30 hari, dan mortalitas 180 hari pada pasien GJDA dengan DM tipe 2.

---

Background : Congestion is the main cause of the worsening condition of chronic heart failure which is also known as acute decompensated heart failure (ADHF). Examination intravascular congestion status in patients with ADHF with low ejection fraction and diabetes mellitus (DM) is very important because it affects the prognosis and has a higher mortality and readmission rate. Examination of intravascular volume status in this population is considered difficult due to increased permeability of the vascular wall, resulting in more interstitial congestion. Several studies used the calculation of estimated plasma volume (ePV) by comparing hemoglobin and hematocrit levels as an indicator of intravascular congestion which acts as a prognostic modality in patients with ADHF and type 2 DM.

Aim : To determine the relationship between estimated plasma volume (eVP) and outcome of length of stay, 30-day-readmission and 180-day-mortality in ADHF patients with low ejection fraction and type-2 DM.

Methods: This is a retrospective cohort involving patients with ADHF, low ejection fraction and type 2 DM from Januay 2016 to January 2021 in National Cardiovascular Center Harapan Kita.

Results: As many as 373 patients fulfilled inclusion criteria. Initial eVP > 5,04 ml/g is associated with 180-day-mortality with sensitivity and specificity of 61% and 59%, respectively (HR 2,12; 95%CI 1,13-3,98; p = 0,019). Pre-discharge eVP is also associated with 30-day-readmission (HR 1,23; IK95 1,05 – 1,46; p = 0,025). Pre-discharge eVP is also significantly correlated with length of stay (B coefficient 0,412, p 0,02)

Conclusion: High estimated plasma volume is associated with length of stay, 30-day-readmission and 180-day-mortality in patients with ADHF, low ejection fraction and type 2 DM."

"Latar belakang: Penderita diabetes melitus tipe 2 memiliki risiko yang lebih tinggi untuk mengalami karies gigi. Fosfat memegang peranan utama dalam kapasitas buffer unstimulated saliva sehingga kadar fosfat berhubungan dengan faktor risiko karies individu. Kondisi ketosis dan hiperparatiroidisme yang menyertai diabetes melitus tipe 2 dapat menyebabkan penurunan buffer fosfat tubuh yang kemudian menurunkan kadar fosfat dalam unstimulated saliva. Tujuan: Menganalisis kadar fosfat dalam unstimulated saliva pada pasien diabetes melitus tipe 2. Metode: Unstimulated saliva 15 subjek diabetes melitus tipe 2 dan 15 subjek non diabetes melitus dikumpulkan untuk kemudian diukur kadar fosfatnya dengan metode phosphomolydate pada alat UV-Vis Spectrophotometer. Hasil: Terdapat perbedaan kadar fosfat yang bermakna (p < 0,05) antara subjek uji dan subjek kontrol. Kesimpulan: Kadar fosfat dalam unstimulated saliva pada pasien diabetes melitus tipe 2 (0,27 ± 0,05 mmol/L) lebih rendah jika dibandingkan dengan individu non diabetes melitus (2,16 ± 0,22 mmol/L) yang mana berdasarkan analisis statistik, hal tersebut berbeda bermakna secara signifikan.

---

Background: Type 2 diabetes mellitus patients have a higher risk to suffer from dental caries. Phosphate plays a primary role in buffer capacity of unstimulated saliva so that phosphate concentration is associated with individual caries risk factors. Ketosis and Hyperparathyroidism conditions that come within type 2 Diabetes Mellitus could decrease the phosphate buffer in the body which then will decrease the phosphate concentration in unstimulated saliva.

Objective: To analyze the phosphate concentration in unstimulated saliva of type 2 diabetes mellitus patients.

Method: Unstimulated saliva of 15 type 2 diabetes mellitus subjects and 15 non-diabetic subjects were collected and then the concentration of phosphate was measured by the phosphomolydate method on UV-Vis Spectrophotometer instrument.

Result: There were significant differences in the phosphate concentration (p <0.05) between test subjects and control subjects.

Conclusion: The phosphate concentration in unstimulated saliva of type 2 diabetes mellitus patients (0.27 ± 0.05 mmol / L) is lower than individuals without diabetes mellitus (2.16 ± 0.22 mmol / L), which is significantly different by statistical analysis."

"ABSTRAK Latar Belakang. Prevalensi disfungsi tiroid lebih tinggi pada pasien diabetes dibandingkan populasiumum. Hipotiroidisme memperburuk komplikasi, morbiditas, mortalitas, dan kualitas hidup pasiendiabetes melitus tipe 2 (DM tipe 2). Faktor risiko hipotiroidisme pada pasien DM tipe 2 selama ini masihkontradiktif dan belum dikaji secara lengkap. Keberadaan sistem skor hipotiroidisme pada pasien DMtipe 2 diperlukan untuk membantu diagnosis dan menapis pasien DM tipe 2 yang memerlukanpemeriksaan laboratorium fungsi tiroid sebagai baku emas diagnosis hipotiroidisme.Tujuan. Mengetahui prevalensi dan determinan hipotiroidisme pada pasien DM tipe 2.Metode. Penelitian dengan desain potong lintang dilakukan di Poliklinik Divisi Metabolik Endokrin(Poliklinik Diabetes) RSCM pada Juli sampai September 2015 dengan metode sampling konsekutif.Subjek menjalani anamnesis, pemeriksaan fisis, dan pemeriksaan laboratorium (TSH dan fT4). Analisisdata dilakukan dengan program statistik SPSS Statistics 17.0 untuk analisis univariat, bivariat,multivariat, dan Receiving Characteristics Operator (ROC) dan SPSS Statistics 20.0 untuk analisisbootstrapping pada Kalibrasi Hosmer-Lemeshow.Hasil. Sebanyak 303 subjek dianalisis untuk mendapatkan proporsi disfungsi tiroid dan 299 subjekdianalisis untuk mendapatkan determinan hipotiroidisme. Sebanyak 23 subjek (7,59%) terdiagnosishipotiroidisme, terdiri dari 43,5% subjek hipotiroid klinis dan 56,5% subjek hipotiroid subklinisberdasarkan Indeks Zulewski dan/atau Indeks Billewicz, dengan 16,7% hipotiroid klinis dan 83,3%hipotiroid subklinis berdasarkan hasil pemeriksaan fT4. Determinan hipotiroidisme pada pasien DMtipe 2 adalah riwayat penyakit tiroid di keluarga dengan OR sebesar 4,719 (95% IntervalKepercayaan/IK 1,07-20,8, p = 0,04), keberadaan goiter dengan OR sebesar 20,679 (95% IK 3,49122,66, p = 0,001),kontrol glikemik yang buruk dengan OR sebesar 3,460 (95%IK 1,075-11,14, p = 0,037), dan adanya sindrom metabolikOR sebesar 25,718 (95% IK 2,21-299,99, p = 0,01). Simpulan. Proporsi hipotiroidisme pada pasien DM tipe 2 adalah 7,59%. Determinan diagnosis dan komponen sistem skor hipotiroidisme pada pasien DM tipe 2 adalah riwayat penyakit tiroid di keluarga, keberadaan goiter, kontrol glikemik yang buruk, dan adanya sindrom metabolik. Sistem skor yang diberi nama Skor Hipotiroid RSCM ini diharapkan menjadi alat bantu diagnosis hipotiroidisme pada pasienDM tipe 2. ABSTRACT Background. Prevalence of thyroid dysfunction is greater in diabetes patients compared to generalpopulation. Hypothyroidism is worsening complications, morbidity, mortality, and quality of life in type2 diabetes mellitus (T2DM) patients. Risk factors of hypothyroidism in T2DM patients are stillcontradictive and not assessed completely. Presence of scoring system to estimate hypothyroidism inT2DM patients are needed to help diagnosing and screening of T2DM patients who need to undergothyroid function test as a gold standard diagnostic for hypothyroidism.Aim. To identify prevalence and estimators of hypothyroidism in T2DM patients.Methods. A cross-sectional study was conducted in Metabolic Endocrine (Diabetes) Outpatient ClinicCipto Mangunkusumo Hospital from July-September 2015 with consecutive sampling method. Allsubjects underwent interview, physical examination, and laboratory testing (TSH and fT4). Analysiswas done by using SPSS Statistics 17.0 for univariate, bivariate, multivariate, and ROC (ReceivingOperator Characteristics) analysis and SPSS Statistics 20.0 for bootstrapping analysis in HosmerLemeshowCalibration. Results. 303 subjects included for proportion study of thyroid dysfunction and 299subjects included for analysis of hypothyroidism determinants. 23 subjects (7,59%) are diagnosed as havinghypothyroidism, consisted of 43,5% clinical hypothyroidism and 56,5% subclinical hypothyroidismbased on clinical scoring index by Zulewski and Billewicz, and 16,7% subjects as having clinicalhypothyroidism and 83,3% subjects as having subclinical hypothyroidism based on fT4 examination.Determinants for hypothyroidism in T2DM patients are family history of thyroid disease with OR 4,719(95% Confident Interval/CI 1,07-20,8, p = 0,04), having goiter or difus struma with OR 20,679 (95%CI 3,49-122,66, p = 0,001), poor glycemic control with OR 3,460 (95% CI 1,075-11,14, p = 0,037), and metabolic syndrome with OR 25,718 (95% CI 2,21-299,99, p = 0,01). Conclusion. Proportion of hypothyroidism in T2DM patients is 7,59%. Determinants and componentsof scoring system of hypothyroidism in T2DM patients consist of family history of thyroid disease,having goiter or difus struma, poor glycemic control, and metabolic syndrome. Scoring system which iscalled RSCM Hypothyroid Score is expected to be a tool for helping diagnosis of hypothyroidism inT2DM patients.;Background. Prevalence of thyroid dysfunction is greater in diabetes patients compared to generalpopulation. Hypothyroidism is worsening complications, morbidity, mortality, and quality of life in type2 diabetes mellitus (T2DM) patients. Risk factors of hypothyroidism in T2DM patients are stillcontradictive and not assessed completely. Presence of scoring system to estimate hypothyroidism inT2DM patients are needed to help diagnosing and screening of T2DM patients who need to undergothyroid function test as a gold standard diagnostic for hypothyroidism.Aim. To identify prevalence and estimators of hypothyroidism in T2DM patients.Methods. A cross-sectional study was conducted in Metabolic Endocrine (Diabetes) Outpatient ClinicCipto Mangunkusumo Hospital from July-September 2015 with consecutive sampling method. Allsubjects underwent interview, physical examination, and laboratory testing (TSH and fT4). Analysiswas done by using SPSS Statistics 17.0 for univariate, bivariate, multivariate, and ROC (ReceivingOperator Characteristics) analysis and SPSS Statistics 20.0 for bootstrapping analysis in HosmerLemeshowCalibration. Results.303subjectsincludedforproportionstudyofthyroiddysfunctionand299subjectsincludedforanalysis of hypothyroidism determinants. 23 subjects (7,59%) are diagnosed as havinghypothyroidism, consisted of 43,5% clinical hypothyroidism and 56,5% subclinical hypothyroidismbased on clinical scoring index by Zulewski and Billewicz, and 16,7% subjects as having clinicalhypothyroidism and 83,3% subjects as having subclinical hypothyroidism based on fT4 examination.Determinants for hypothyroidism in T2DM patients are family history of thyroid disease with OR 4,719(95% Confident Interval/CI 1,07-20,8, p = 0,04), having goiter or difus struma with OR 20,679 (95%CI 3,49-122,66, p = 0,001), poor glycemic control with OR 3,460 (95% CI 1,075-11,14, p = 0,037), and metabolic syndrome with OR 25,718 (95% CI 2,21-299,99, p = 0,01).Conclusion. Proportion of hypothyroidism in T2DM patients is 7,59%. Determinants and componentsof scoring system of hypothyroidism in T2DM patients consist of family history of thyroid disease,having goiter or difus struma, poor glycemic control, and metabolic syndrome. Scoring system which iscalled RSCM Hypothyroid Score is expected to be a tool for helping diagnosis of hypothyroidism inT2DM patients.;Background. Prevalence of thyroid dysfunction is greater in diabetes patients compared to generalpopulation. Hypothyroidism is worsening complications, morbidity, mortality, and quality of life in type2 diabetes mellitus (T2DM) patients. Risk factors of hypothyroidism in T2DM patients are stillcontradictive and not assessed completely. Presence of scoring system to estimate hypothyroidism inT2DM patients are needed to help diagnosing and screening of T2DM patients who need to undergothyroid function test as a gold standard diagnostic for hypothyroidism.Aim. To identify prevalence and estimators of hypothyroidism in T2DM patients.Methods. A cross-sectional study was conducted in Metabolic Endocrine (Diabetes) Outpatient ClinicCipto Mangunkusumo Hospital from July-September 2015 with consecutive sampling method. Allsubjects underwent interview, physical examination, and laboratory testing (TSH and fT4). Analysiswas done by using SPSS Statistics 17.0 for univariate, bivariate, multivariate, and ROC (ReceivingOperator Characteristics) analysis and SPSS Statistics 20.0 for bootstrapping analysis in HosmerLemeshowCalibration. Results.303subjectsincludedforproportionstudyofthyroiddysfunctionand299subjectsincludedforanalysis of hypothyroidism determinants. 23 subjects (7,59%) are diagnosed as havinghypothyroidism, consisted of 43,5% clinical hypothyroidism and 56,5% subclinical hypothyroidismbased on clinical scoring index by Zulewski and Billewicz, and 16,7% subjects as having clinicalhypothyroidism and 83,3% subjects as having subclinical hypothyroidism based on fT4 examination.Determinants for hypothyroidism in T2DM patients are family history of thyroid disease with OR 4,719(95% Confident Interval/CI 1,07-20,8, p = 0,04), having goiter or difus struma with OR 20,679 (95%CI 3,49-122,66, p = 0,001), poor glycemic control with OR 3,460 (95% CI 1,075-11,14, p = 0,037), and metabolic syndrome with OR 25,718 (95% CI 2,21-299,99, p = 0,01).Conclusion. Proportion of hypothyroidism in T2DM patients is 7,59%. Determinants and componentsof scoring system of hypothyroidism in T2DM patients consist of family history of thyroid disease,having goiter or difus struma, poor glycemic control, and metabolic syndrome. Scoring system which iscalled RSCM Hypothyroid Score is expected to be a tool for helping diagnosis of hypothyroidism inT2DM patients."